scholarly journals Primary Diffuse Large B-Cell Lymphoma Localized to the Lacrimal Sac: A Case Presentation and Review of the Literature

2016 ◽  
Vol 2016 ◽  
pp. 1-3
Author(s):  
Kevin Zarrabi ◽  
Ved Desai ◽  
Brandom Yim ◽  
Theodore G. Gabig
Keyword(s):  
B Cell ◽  
Rare Case ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Excisional Biopsy ◽  
Treatment Modalities ◽  
Lacrimal Sac ◽  
Ocular Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

We report a rare case of diffuse large B-cell lymphoma (DLBCL) of the lacrimal sac in a 50-year-old male. The incidence of primary ocular lymphoma is low and it is considered a rare disease. Moreover, reports of ocular DLBCL are uncommon and the disease remains poorly characterized. Our patient presented for management of osteomyelitis and was incidentally found to have a painless swelling and cyst around his right eye. A PET/CT scan revealed hypermetabolic activity within the lacrimal sac and a subsequent excisional biopsy of the mass yielded histopathology consistent with DLBCL. Consequently, the patient underwent treatment with R-CHOP therapy. The patient responded well to chemotherapy with a substantial shrinkage in tumor burden and the disease remained localized. Herein, we present a rare case of primary ocular lymphoma, highlight the importance of early diagnosis, and review current treatment modalities.

scholarly journals Rare case of distal tibial Diffuse Large B-cell Lymphoma (DLBCL) in a Diabetic with Charcot Neuroarthropathy

2021 ◽  
pp. 100045
Author(s):  
Resident Physician Trevor Klinkner ◽  
Margaret Kerins ◽  
Devrie Stellar ◽  
Corine Creech ◽  
Richard Derner
Keyword(s):  
B Cell ◽  
Rare Case ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Charcot Neuroarthropathy ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Treatment Modalities and Survival Outcomes for Sinonasal Diffuse Large B‐Cell Lymphoma

2021 ◽  
Author(s):  
Brandon M. Lehrich ◽  
Arash Abiri ◽  
Khodayar Goshtasbi ◽  
Jack Birkenbeuel ◽  
Tyler M. Yasaka ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Treatment Modalities ◽  
Survival Outcomes ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Pitfalls of Frozen Section in Gynecological Pathology: A Rare Case of Ovarian Lymphoma in an HIV-Positive Woman Resembling Dysgerminoma on Frozen Section

2018 ◽  
Vol 27 (4) ◽  
pp. 387-389 ◽  
Author(s):  
Qing Wang ◽  
Raul Rodriguez ◽  
Jenna Z. Marcus ◽  
Lisa Podolsky ◽  
Damali Campbell ◽  
...  
Keyword(s):  
B Cell ◽  
Rare Case ◽  
Cell Lymphoma ◽  
Frozen Section ◽  
B Cell Lymphoma ◽  
Hiv Positive ◽  
Primary Lymphoma ◽  
Positive Woman ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Primary lymphoma of the ovary, particularly in an HIV-positive woman, is exceptionally rare, and ovarian lymphoma may not be considered at the time of intraoperative consultation. In this article, we present a case in an HIV-positive woman thought to be a dysgerminoma at the time of frozen section, but which was found to be a diffuse large B-cell lymphoma of the ovary.

scholarly journals Encephalomyeloradiculoneuropathy Revealing a Rare Case of Intravascular Large B-Cell Lymphoma

Cureus ◽  
2021 ◽  
Author(s):  
Jehanne Aasfara ◽  
Fadila Guessous ◽  
Abderahmane Al Bouzidi ◽  
Hamid Ouhabi ◽  
David Schiff
Keyword(s):  
B Cell ◽  
Rare Case ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Diffuse primary large B cell lymphoma of leg type presenting on the breast: a rare case of surgical excision

2011 ◽  
Vol 2011 (dec08 1) ◽  
pp. bcr0520114286-bcr0520114286
Author(s):  
S. Bertaud ◽  
S. Dindyal ◽  
C. Kaur ◽  
J. Vaidya
Keyword(s):  
B Cell ◽  
Rare Case ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Surgical Excision ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Metachronous Diffuse Large B-Cell Lymphoma of the Breasts: A Case Report and Literature Review

2021 ◽  
Vol 14 (6) ◽  
Author(s):  
Mastane Saneii ◽  
Pedram Fadavi ◽  
Kambiz Novin ◽  
Maryam Garousi
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Maximum Level ◽  
Treatment Modalities ◽  
Regional Lymph Nodes ◽  
Case Presentation ◽  
Large B Cell Lymphoma ◽  
One Year ◽  
Large B Cell

Introduction: PBL is a rare form of extranodal lymphoma. The most common pathology is diffuse large B cell lymphoma and most patients are diagnosed at stages 1 and 2. The therapeutic options undertaken so far include surgery, radiotherapy, and chemotherapy Case Presentation: The patient was a 54-year old woman with localized primary breast DLBCL. The patient underwent 6 courses of chemotherapy with an RCHOP regimen followed by radiotherapy of the breast and regional lymph nodes with a 40 Gy dose. The patient was in complete remission on PET scan 3 months later. Around one year after, the patient experienced relapse in the contralateral breast. Conclusions: In the pattern of relapse of patients, there is a tendency for extranodal relapse. In some studies maximum level of relapse occurring in CNS and some advocate CNS prophylaxis in these patients. The best outcome is for patients treated with chemotherapy including rituximab followed by radiation. We reviewed some studies in the aspect of treatment modalities and site of relapsed.

A case of primary breast diffuse large B cell lymphoma

2021 ◽  
Vol 148 (12) ◽  
pp. 102-107
Author(s):  
Trinh Le Huy ◽  
Tran Dinh Anh
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Excisional Biopsy ◽  
Needle Aspiration ◽  
Non Hodgkin Lymphoma ◽  
Large B Cell Lymphoma ◽  
Painless Mass ◽  
Large B Cell

Primary breast diffuse large B-cell lymphoma (DLBCL) is a rare non-Hodgkin’s lymphoma with limited data. We here report a case of primary breast diffuse large B-cell lymphoma mimicking breast cancer. A 52-year-old woman had a painless mass in her right breast. Fine needle aspiration cytology and core biopsy were performed which suggested malignant features but could not confirm the specific subtype. Excisional biopsy then was conducted revealing non-Hodgkin lymphoma, which was subsequently confirmed with histopathology and diagnosed as diffuse large B-cell lymphoma (DLBCL). A chest computed tomography scan revealed a 3.5 cm sized breast mass with skin thickening and modest lymphadenopathy in the ipsilateral axilla. The patient received six courses of R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone plus rituximab) chemotherapy, then whole breast radiation (30Gy in 15 fractions). At 12 months of follow-up, the patient survives with no evidence of disease. No morbidities occurred in this patient during the follow-up period. We briefly review the current practice pattern in patients with primary breast diffuse large B-cell lymphoma.

scholarly journals Trends in Survival of Patients with Primary Gastric Diffuse Large B-Cell Lymphoma: An Analysis of 7051 Cases in the SEER Database

2018 ◽  
Vol 2018 ◽  
pp. 1-7
Author(s):  
Pan-pan Liu ◽  
Yi Xia ◽  
Xi-wen Bi ◽  
Yu Wang ◽  
Peng Sun ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
Survival Rates ◽  
Multivariable Analysis ◽  
B Cell Lymphoma ◽  
Treatment Modalities ◽  
Seer Database ◽  
Limited Information ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Treatment modalities for primary gastric diffuse large B-cell lymphoma (PG-DLBCL) have changed significantly during the past decades. However, limited information on the trends of clinical outcome of PG-DLBCL patients has been reported. Here, we conducted a retrospective analysis using the Surveillance, Epidemiology, and End Results (SEER) database to compare the survival trends of PG-DLBCL patients from 1973 to 2014. Patients were divided into 2 eras based on the year of diagnosis in relation to immunotherapy with the anti-CD20 antibody rituximab that was approved in 1997 and became a widely used drug in 2000. There was a significant improvement in survival among PG-DLBCL patients diagnosed in the 2001–2014 era (n=4186) compared to patients diagnosed in the 1973–2000 era (n=2865), with the 5-year overall survival rates of 53% and 47%, respectively (p=0.001). Multivariable analysis revealed that the 2001–2014 era (HR = 0.892, p=0.001) was associated with lower mortality and that patients of older age, Black race, advanced stage, and male gender were associated with poor prognosis. Although outcome of PG-DLBCL has significantly improved over time, more effective therapies are needed for older patients to further improve their survival.

Sign in / Sign up

Export Citation Format

Share Document